| Value | ₹200.0 Cr |
|---|---|
| Execution period | 12-18 months |
NSE filing, NSE: INDORAMA. Summary written from the filing by ALFA Finder's alert engine.
Indo Rama Synthetics (India) Ltd: key numbers
- Share price
- ₹74.54
- Market cap
- ₹1,946 Cr
- Revenue (annual)
- ₹4,910 Cr
- Net profit (annual)
- ₹150.2 Cr
- P/E (TTM)
- 9.2×Sector 50.4×
- Promoter holding
- 75.00%+0.16% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo Rama Synthetics (India) Ltd
All →Indo Rama Synthetics (India) Earnings Call Transcript: Key Takeaways
Indo Rama is stabilizing after massive capacity expansions, showing significant profit recovery as margins expand.
- Call
- Guides 15% growth
Indo Rama Synthetics (India) Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹1,340.6 Cr (+9.8%), EBITDA ₹117.7 Cr (+46%, 8.8% margin), PAT ₹74.1 Cr (+202%). H1 revenue down ~10%; ₹200 Cr specialty expansion planned.
Indo Rama Synthetics (India) Results Update
Indo Rama Synthetics reported Q2 FY27 revenue of ₹1,344 crore, with a 10% YoY growth and PAT growing 202% to ₹74 crore.
Indo Rama Synthetics (India) Q2 FY27 Results: Net Profit ₹74.1 Cr, Up 201.2% YoY
Indo Rama Synthetics (India) Ltd reported revenue from operations of ₹1,341 Cr (+9.8% YoY) and net profit of ₹74.1 Cr (+201.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.1 Cr · +201.2% YoY
Indo Rama Synthetics (India) Board Meeting Date
Indo Rama Synthetics will hold a board meeting on 16 October 2026 to consider unaudited standalone and consolidated financial results for the quarter ended September 2026.
Indo Rama Synthetics (India) Other Announcement
Indo Rama Synthetics (India) Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required under SEBI regulations.
Other capacity expansion announcements
All →Global Health Capacity Expansion: ₹997 Cr Investment
Medanta plans a 500-bed Ghaziabad hospital over 3-4 years. Project cost is Rs 997 Crore, funded by internal accruals and debt.
- Value
- ₹997.0 Cr
- Execution
- 3-4 years, phased
- hospital beds
- 500.0 beds
Gujarat Inject (Kerala) Capacity Expansion
Gujarat Inject Kerala Ltd leased two Ahmedabad industrial premises for factory and R&D use. The five-year deals include 5% escalation and a two-year lock-in.
- Execution
- 5 years (2-year lessee lock-in)
Aelea Commodities Capacity Expansion: ₹114 Cr Investment
Aelea's board approved ₹114 crore to add 90 MT manufacturing capacity and build a staff housing colony in Surat. Completion expected within 30 months from February 2027.
- Value
- ₹114.0 Cr
- Execution
- 30 months from February 2027
- manufacturing capacity addition
- 90.0 MT
Kaynes Technology India Capacity Expansion
Kaynes Technology has incorporated a wholly owned subsidiary, Kaynes Arabia Electronics Company, in Saudi Arabia to manufacture electronic products for GCC markets. The company holds 100% ownership and the authorised share capital is SAR 100,000.
Vaibhav Vyapaar Capacity Expansion
Vaibhav Vyapaar opened a new business office in Bangalore, commencing operations on 02 November 2026. The approximately 5,500 sq ft office supports operational expansion.
- office area
- 5500.0 sq ft
Borana Weaves Capacity Expansion: ₹49.92 Cr Investment
Borana Weaves plans 384 new looms, adding 110.60 million metres of yearly capacity. The Rs 49.92 Crore investment will be phased through March 2027.
- Value
- ₹49.92 Cr
- Execution
- Phase 1 by December 2026; Phase 2 by March 2027
- annual greige fabric production capacity
- 110.6 million metres per year